GW Pharmaceuticals Ltd.(NASDAQ : GWPH)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.60%||163.54||0.7%||$1305.95m|
|LLY||Eli Lilly & Co.||-1.93%||323.65||1.1%||$1056.02m|
|BMY||Bristol-Myers Squibb Co.||-0.82%||71.12||1.0%||$763.08m|
|MRK||Merck & Co., Inc.||-0.52%||86.19||0.7%||$687.90m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-4.41%||200.16||8.2%||$210.64m|
|GBT||Global Blood Therapeutics, Inc.||0.04%||68.10||5.4%||$190.73m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.21%||151.22||0.0%||$178.64m|
|IDXX||IDEXX Laboratories, Inc.||-1.81%||325.80||3.9%||$175.84m|
|HZNP||Horizon Therapeutics Plc||-1.28%||61.89||5.4%||$160.55m|
|NVO||Novo Nordisk A/S||-0.74%||99.65||0.1%||$140.44m|
GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.